Ageing is the biggest risk factor for impaired cardiovascular health, with cardiovascular disease being the cause of death in 40 % of individuals over 65 years old. Ageing is associated with an increased prevalence of atherosclerosis, coronary artery stenosis and subsequent myocardial infarction, thoracic aortic aneurysm, valvular heart disease and heart failure. An accumulation of senescence and increased inflammation, caused by the senescence-associated secretory phenotype, have been implicated in the aetiology and progression of these age-associated diseases. Recently it has been demonstrated that compounds targeting components of anti-apoptotic pathways expressed by senescent cells can preferentially induce senescence cells to apoptosis and have been termed senolytics. In this review, we discuss the evidence demonstrating that senescence contributes to cardiovascular disease, with a particular focus on studies that indicate the promise of senotherapy. Based on these data we suggest novel indications for senolytics as a treatment of cardiovascular diseases which have yet to be studied in the context of senotherapy. Finally, while the potential benefits are encouraging, several complications may result from senolytic treatment. We, therefore, consider these challenges in the context of the cardiovascular system.

衰老是心血管健康受损的最大风险因素，心血管疾病是 40% 的 65 岁以上人群的死亡原因。衰老与动脉粥样硬化、冠状动脉狭窄和随后的心肌梗塞、胸主动脉瘤、瓣膜性心脏病和心力衰竭的患病率增加有关。由衰老相关的分泌表型引起的衰老积累和炎症增加与这些年龄相关疾病的病因和进展有关。最近已经证明，靶向由衰老细胞表达的抗凋亡途径成分的化合物可以优先诱导衰老细胞凋亡，并被称为senolytics。在本次审查中，我们讨论了表明衰老导致心血管疾病的证据，特别关注表明衰老疗法前景的研究。基于这些数据，我们提出了 senolytics 作为心血管疾病治疗的新适应症，这些疾病尚未在 Senotherapy 的背景下进行研究。最后，虽然潜在的好处令人鼓舞，但抗衰老治疗可能会导致一些并发症。因此，我们在心血管系统的背景下考虑这些挑战。虽然潜在的好处令人鼓舞，但抗衰老治疗可能会导致一些并发症。因此，我们在心血管系统的背景下考虑这些挑战。虽然潜在的好处令人鼓舞，但抗衰老治疗可能会导致一些并发症。因此，我们在心血管系统的背景下考虑这些挑战。